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Background: This analysis of pooled data evaluates treatment outcomes of patients with schizophrenia receiving
maintenance treatment with olanzapine long-acting injection (OLAI) by means of a categorical approach addressing
the symptomatic and functional status of patients at different times.
Methods: Patients were grouped into 5 categories at baseline, 6 months, and 12 months. Shifts between
categories were assessed for individual patients and factors associated with improvement were analyzed. 1182
patients from 3 clinical trials were included in the current analysis.
Results: At baseline, 434 (36.8%) patients had minimal Positive and Negative Syndrome Scale (PANSS) symptoms
but seriously impaired Heinrich Carpenter’s Quality of Life Scale (QLS) functioning; 303 (25.6%) had moderate to
severe symptoms and seriously impaired function; 208 (17.6%) had mild to moderate symptoms but good
functioning, and 162 (13.7%) had minimal symptoms and good functioning. Baseline category was significantly
associated with Clinical Global Impression – Severity (CGI-S), extrapyramidal symptoms, working status, age, and
number of previous episodes. The majority of all patients starting OLAI treatment maintained or improved (62% at
6 months and 52% at 12 months) their symptom and functioning levels on OLAI maintenance treatment. Less than
8% of the patients showed worsening of symptoms or functioning. An improvement in category was associated
with high PANSS positive and low CGI-S scores at baseline.
Conclusions: We present evidence that a composite assessment of schizophrenic patients including symptom
severity and functioning is helpful in the evaluation of maintenance treatment outcomes. This approach could also
be useful for the assessment of treatment options in clinical practice.
The trials from which data are reported here were registered on clinicaltrials.gov as NCT00088491, NCT00088465,
and NCT00320489.Background
Treatment of schizophrenia is a long-term effort, not
only aiming to control symptoms but also to maintain
or improve functioning, allowing patients to participate
in paid employment and other societal activities. Since
poor treatment adherence is a major risk for relapse, the
use of long-acting injection (“depot”) formulations of* Correspondence: joseph.peuskens@uc-kortenberg.be
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reproduction in any medium, provided the orantipsychotics should have advantages in maintenance
treatment of patients with schizophrenia with a history
of non-compliance and relapse [1-3].
In recent years, the atypical antipsychotics risperidone,
paliperidone, and olanzapine became available as depot for-
mulations allowing effective long-acting antipsychotic treat-
ment while avoiding some of the side effects of the earlier
available depot formulations of typical antipsychotics.
The present pooled analysis assesses the overall deve-
lopment of the symptomatic and functional status ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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studies with the olanzapine long-acting injection (OLAI)
formulation. In all studies, maintenance treatment out-
comes of schizophrenia symptoms were measured by
the positive and negative Syndrome scale (PANSS), and
functioning by the Heinrich Carpenter’s quality of life
scale (QLS). In this scale, functioning is assessed in par-
ticular with the QLS Interpersonal Relations and QLS
Instrumental Role domains. Analyses were performed on
the data collected at baseline and after 6 and 12 months
of patient participation in these studies with OLAI.
A comprehensive description of the status of patients
with schizophrenia should include an assessment of
schizophrenia symptoms and of patient functioning.
Consequently, the present analysis is based on a classifi-
cation of patients into 5 distinct clusters or categories (A
to E) that were previously identified in a population of
patients with schizophrenia treated over approximately
30 weeks with oral antipsychotics [4]. This cluster ana-
lysis by Lipkovich et al. also provided the categorization
rules, based on a PANSS 5-factor model [4] and QLS
scores, allowing a categorical classification of patients
with high specificity and sensitivity. Changes in PANSS
and QLS scores over time may result in a change in ca-
tegory for a particular patient.
The objective of the analyses reported is to evaluate
how non-acute schizophrenia patients with different
baseline status develop in terms of their symptoms and
functioning during maintenance treatment as analyzed
by changes in their assignment to the pre-defined ca-
tegories consisting of a combination of symptomatic sta-
tus and level of functioning. Further, factors associated
with categorical improvement in symptoms and/or func-
tioning are identified through statistical modeling. As an
alternative approach to the cluster analysis approach, a
remission analysis based on the Andreasen remission
criteria was performed [5]. Our results may add import-
ant information about factors associated with long-term
benefits for patients and society when patients are re-




The present analysis was performed on data from
patients with schizophrenia who were not acutely ill and
were receiving maintenance treatment with OLAI medi-
cation. These patients were enrolled in 3 clinical trials:
HGKA, HGLQ, and HGKB. Patients in HGKB could
have previously participated in studies LOBS, HGKA,
and HGJZ. All 5 studies were sponsored by Eli Lilly &
Company. The studies used in the analyses had mea-
surements of PANSS and of QLS available at baseline,
and at 6 months (± 1 month). PANSS and QLS datawere also evaluated at 12 ± 3 months (1 year). All
patients gave written informed consent prior to partici-
pation in any of the studies. The main study design fea-
tures of the studies included in the pooled analysis are
summarized below:
 Study HGKA was a 6 month, double-blind,
randomized, multicenter study on 1065 clinically
stable outpatients. 753 completed the reporting
interval [6]. Of those, 599 patients with OLAI dose
of 300 mg/2 weeks (n = 140), 405 mg/4 weeks
(n = 314), or 150 mg/2 weeks (n = 140) were
included in the analysis. Patients on oral olanzapine
as well as on OLAI at the very low dose of 45 mg/
2 weeks (given in lieu of placebo) were not included
in the present analysis.
 Study HGLQ was a 2 year, open-label, randomized,
multicenter study comparing the long-term
treatment effectiveness and safety of OLAI with oral
olanzapine. 261 patients who received an injection
of 405 mg OLAI at baseline followed by individual
dosing of 150 mg to 405 mg/4 weeks were included
in the analysis [7].
 Study HGKB was an open label extension safety
study offered to patients who completed or
discontinued from study HGKA, study HGJZ
(investigating superiority of OLAI vs. placebo), or
study LOBS (investigating product performance and
bioavailability of OLAI). The initial dose of OLAI
was 210 mg with a second injection after 2 weeks
(150–405 mg). Subsequently, individual dosing with
dosing intervals of 2 to 4 weeks and a maximum
cumulative total dose of 600 mg during a 4-week
period was allowed [8].
All study protocols were approved by institutional re-
view boards at each site.
Data collected during the acute treatment periods in
the short term studies HGJZ and LOBS were not
included in the present analysis because these patients
were either acutely ill (HGJZ) or received an OLAI do-
sage schedule specifically for pharmacokinetic evalua-
tions (LOBS). Therefore, these data were not helpful for
assessing maintenance treatment effects of OLAI. For
the present analysis, baseline for patients from these
studies was defined as entry into study HGKB. Baseline
for patients in HGKA and HGLQ was the first assess-
ment in these studies.
The following baseline variables collected in all three
studies were used for statistical modeling: age, baseline
category, baseline remission status, extrapyramidal
symptoms (EPS), geographic region, CGI-S score , num-
ber of previous episodes, PANSS total and subscores
(anxiety/depression, disorganized, hostility, negative,
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tions, instrumental role functioning), study indicator
(HGKA, HGLQ, HGKB), gender, time since diagnosis,
weight, and employment status (unemployed, working,
retired).
Overall data from 1182 patients at baseline, 864
patients at 6 months and 687 patients at 12 months were
used for the present analysis.
Outcome measures
Psychiatric symptoms were assessed using the PANSS
[9]. In the present study, for creating the patient catego-
ries, we followed the PANSS factor analysis by Marder
et al. [10]. The 5 main factor scores were: 1) PANSS
Negative factor (PANSS NEG; 7 items: 8–11,13,21,30);
2) PANSS Positive factor (PANSS POS; 8 items:
1,3,5,6,14,15,23,26); 3) PANSS Disorganized factor
(PANSS DIS; 7 items: 2,12,19,24,25,27,29); 4) PANSS
Hostility factor (PANSS HOS; 4 items: 4,7,22,28); and 5)
PANSS Anxiety/Depression factor (PANSS DEP; 4 items:
16,17,18,20). Scores on individual PANSS items ranged
from 1 (no symptoms) to 7 (severe symptomatology).
PANSS factor scores were divided by the number of
items per factor (i.e. normalized factor scores range from
1 to 7).
Functioning in all studies was assessed with the QLS
total score. The QLS items range from 0 (worst) to 6
(best). For the analysis we used the 2 QLS domains
(interpersonal relations and instrumental role [11]) as
categorizers identified in the Lipkovich et al [4] cluster
analysis.
 QLS Interpersonal Relations domain measuring the
qualitative aspects of interpersonal relationships;
consisting of 8 items, and
 QLS Instrumental Role domain measuring the level
of and the satisfaction with occupational role
functioning; consisting of 4 items.
These 2 domains of the QLS represent the part of the
QLS that reflects the functional aspects of a patient's
quality of life including the patient's ability to work and
to maintain relationships with others. Overall scores for
domains as well as the total score were divided by the
number of the respective items.
Based on cluster analysis reported in Lipkovich et al
[4], patients with schizophrenia can be grouped into 5
different clusters (categories) based on severity of their
clinical symptoms as measured by PANSS and on the
level of their functioning, as measured by the QLS Inter-
personal and QLS Instrumental domains. For the
current analysis, the classification rules of this previous
publication were used. The category cutoffs used, as
determined by a classification tree algorithm [CART,[12]], were based on the QLS Instrumental domain score
and on the PANSS DIS and PANSS POS subscores.
These decision rules do not yield mutually exclusive ca-
tegories but are able to separate categories with high
specificity between 87% and 98%.
The categories contain patients with good symptom
control and moderate to good functioning (Category A),
patients with either good symptom control and impaired
functioning (Category B) or insufficient symptom con-
trol and moderate to good functioning (Category C), and
the most severe categories include patients with mode-
rate to severe symptoms and impaired functioning
(Category D) and with severe psychiatric symptoms and
impaired functioning (Category E).
Categorical improvement of a patient was defined as
moving from Categories B or C to Category A, or from
Categories D or E to Categories A, B, or C. Thus,
patients in Category A could not improve and were
excluded from the analysis of improvement. Worsening
of a patient was defined as moving from Category A to
Categories B, C, D, or E or from Categories B or C to
Categories D or E. As only few patients were categorized
in Categories D and E both categories were combined
and could not worsen. Thus, they were excluded from
the analysis of worsening.
As an additional measure of long term treatment out-
comes in addition to the cluster analysis described
above, the proportion of patients in remission and sus-
tained remission were analyzed. Remission was defined
based on the Andreasen criteria [5]. Sustained remission
was defined as maintaining simultaneous ratings of
“mild” or better (score of 1, 2, or 3) over a 6 month
period on the following items of the PANSS: delusions,
conceptual disorganization, hallucinatory behavior, man-
nerisms/posturing, unusual thought content, blunted
affect, social withdrawal, and lack of spontaneity.
Cross-sectional remission at baseline or any other spe-
cific time point was defined similarly, but excluded the
requirement for maintenance over a 6 month period.
Statistical procedure
Patient baseline and post baseline characteristics were
summarized using descriptive statistics and compared
among baseline categories using analysis of variance
(ANOVA) for continuous variables and chi-square test
for categorical variables. Reasons for discontinuation
and baseline characteristics of patients remaining in the
analyses versus those discontinuing within 6 months
were summarized and compared using t-test for con-
tinuous variables and chi-square test for categorical
variables.
Baseline factors were assessed for their association
with categorical improvement using stepwise logistic re-
gression. These analyses were performed for categorical
Table 1 Baseline predictors associated with categorical improvement after 6 Months and 12 Months of treatment with
OLAI
Logistic regression statistics
Model Odds ratio 95% CI of Odds ratio p-value (for effect)
Single variable model 6 Months
Age [1 year] 0.989 0.975; 1.002 0.0937
Time since diagnosis [1 year] 0.979 0.959; 0.998 0.0327
Working status
unemployed vs. retired 1.023 0.620; 1.688 0.9287
working vs. retired 1.564 0.925; 2.644 0.0948
Clinical Study
HGKA vs. HGKB 1.890 1.262; 2.830 0.0020
HGLQ vs. HGKB 0.972 0.603; 1.566 0.9068
Baseline category
C vs. B 3.007 1.966; 4.600 <0.0001
D vs. B 6.656 4.386; 10.099 <0.0001
E vs. B 3.043 1.585; 5.841 0.0008
CGI-S [1 point higher at baseline] 0.787 0.659; 0.941 0.0084
PANSS total [1 point higher at baseline] 1.010 1.000; 1.020 0.0622
PANSS positive 1.553 1.210; 1.992 0.0005
PANSS anxiety/depression 1.326 1.066; 1.649 0.0111
PANSS hostility 1.253 0.992; 1.583 0.0586
QLS total [1 point higher at baseline] 1.135 1.035; 1.245 0.0072
QLS Instrumental role funct. 1.151 1.026; 1.291 0.0162
QLS Interpersonal relations 1.159 1.008; 1.333 0.0381
Remission baseline [yes vs, no] 1.061 0.778; 1.449 0.7078
Remission 6 months [yes vs. no] 2.420 1.670; 3.507 <0.0001
Stepwise multivariate logistic regression 6 Months
PANSS positive 2.840 1.834; 4.399 <0.0001
CGI-S 0.619 0.463; 0.828 0.0012
Single variable model 12 Months
Clinical Study
HGKA vs. HGKB 1.592 1.048; 2.418 0.0294
HGLQ vs. HGKB 0.905 0.562; 1.458 0.6811
Baseline category
C vs. B 3.316 2.085; 5.271 <0.0001
D vs. B 6.936 4.351; 11.057 <0.0001
E vs. B 5.879 2.742; 12.605 <0.0001
PANSS total 1.018 1.006; 1.029 0.0024
PANSS positive 1.798 1.354; 2.387 <0.0001
PANSS anxiety/depression 1.370 1.066; 1.761 0.0141
PANSS disorganized 1.390 1.062; 1.821 0.0167
PANSS hostility 1.565 1.193; 2.053 0.0012
QLS total 1.157 1.045; 1.281 0.0049
QLS Instrumental role funct. 1.178 1.038; 1.337 0.0112
QLS Interpersonal relations 1.167 0.999; 1.363 0.0520
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Table 1 Baseline predictors associated with categorical improvement after 6 Months and 12 Months of treatment with
OLAI (Continued)
Remission baseline 1.013 0.720; 1.426 0.9391
Remission 12 months 2.628 1.710; 4.039 <0.0001
Stepwise multivariate logistic regression 12 Months
PANSS positive 1.537 1.129; 2.093 0.0063
In total, 22 variables were assessed in the single variable logistic regression models. Variables in bold were identified as potentially overlapping variables and were
not included in the stepwise multivariate logistic regression model. CGI-S: Clinical Global Impression – Severity, CI: confidence interval, PANSS: Positive and
Negative Symptoms Score, QLS: Heinrich Carpenter’s Quality of Life Scale.
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12 months (see definition of categorical improvement in
'Outcome measures' section).
At the first step of modeling reported in Table 1 under
the ‘Single variable model’ heading, a number of single
factor logistic regression models were fitted. Each model
evaluated a single baseline variable in relation to the out-
come (categorical improvement) without adjustment for
other variables. The following baseline variables were
used as potential predictors: age, baseline category, base-
line remission status, extrapyramidal symptoms (EPS),
geographic region, Clinical Global Impression Severity
(CGI-S) score [13], number of previous episodes, PANSS
total and subscores (anxiety/depression, disorganized,
hostility, negative, positive), QLS total and domains
(interpersonal relations, instrumental role functioning),
study indicator (HGKA, HGLQ, HGKB), gender, time
since diagnosis, weight, and employment status (un-
employed, working, retired). This approach allowed for
screening of a high number of correlated variables and
provided additional information about potential associa-
tion prior to adjustment for other variables. SAS auto-
matic procedures would exclude all patients who have
missing values for at least one of the variables and have
convergence issues with correlated variables, and there-
fore were not used. The number of covariates entering
at the second step in the multiple logistic regression
model was reduced by manual variable selection based
on the first step modeling results to avoid over-fitting.
At the second step of modeling, reported in Table 1
under the ‘Stepwise multivariate logistic regression’
heading all baseline variables that were identified as po-
tentially significant (p < 0.1 in the single factor model)
were simultaneously included in a multivariate model
for stepwise selection of covariates based on significance
cut-off of p < 0.1 entry into the combined model. After
the stepwise procedure only those variables that were in-
dependently predicting outcome remained in the model.
Other variables were excluded due to co-dependencies,
even if they were significant as a single predictor. To
avoid “overlap” in predictors and issues with co-linearity,
variables derived from predictors already included in the
model (total scores for the PANSS and QLS scales,remission status, and baseline category) were not used
in the multiple regression model. No imputation of
missing data was used. SAS version 9.1.3 (SAS Institute,
Cary, N.C.) was used for all analyses.
Results
Baseline categories and dropouts at 6 months
1182 patients with baseline PANSS and QLS data avail-
able were included in the current analysis. Patients
included in the analysis were 66.8% males, had a mean
age of 39.6 years (range: 18 to 74 years), and 46.5% were
from the Americas, 44.8% from Europe and 8.6% from
other areas. Baseline mean PANSS total score was 62.1
(±16.4), and mean QLS total score was 1.65 (±1.81). EPS
were reported for 13.9% of the patients.
339 patients (28.7%) discontinued from one of the 3
respective studies during the first 6 months. The reten-
tion rate by study was 75.3% (HGKA, 451/599); 73.6%
(HGLQ, 192/261), and 69.5% (HGKB, 221/318). Of all
864 patients with data at 6 months (i.e. 21 patients dis-
continuing at the 6 months visit had still data available),
787 (91.1%) had sufficient data available for the assess-
ment of categorical changes in schizophrenia symptoms
(PANSS) and health-related functioning (QLS).
The most common (>10% of all discontinuations)
reasons for discontinuations in the first 6 months
were subject decision (129, 38.1%), adverse event (56,
16.5%), lack of efficacy (41, 12.1%), and lost to follow-
up (38, 11.2%).
We have compared baseline characteristics of patients
who remained for at least 6 months in the studies with
those who discontinued (Table 2). Patients discontinuing
early had more severe psychiatric symptoms at baseline –
in particular acute symptoms as measured by the PANSS
POS, PANSS HOS, and PANSS DEP scores. Higher rates
were also found for other baseline measurements, reflect-
ing decreased functioning such as CGI-S, working status,
baseline remission, and QLS instrumental role function-
ing. No significant differences between dropouts and
patients remaining in the studies were seen for age, geo-
graphic region, gender, PANSS NEG and PANSS DIS
scores, QLS interpersonal relations domain, EPS at
baseline, and number of previous episodes.
Table 2 Baseline characteristics for all patients and for patients remained vs. patients who discontinued within
6 months from baseline
Patients n (%)
Characteristic (%) Remained (N = 843) Discontinued (N= 339) Total (N = 1182) p-value
Geographic Region 0.129
Western Europe 148 (68.8) 67 (31.2) 215
Eastern Europe 237 (75.2) 78 (24.8) 315
Americas 380 (69.1) 170 (30.9) 550
Other 78 (76.5) 24 (23.5) 102
Gender 0.391
Female 274 (69.7) 119 (30.3) 393
Male 569 (72.1) 220 (27.9) 789
EPS 0.180
No 542 (74.0) 190 (26.0) 732
Yes 113 (68.9) 51 (31.1) 164
Working Status 0.003
Unemployed disab. 349 (70.2) 148 (29.8) 497
Paid work 181 (81.2) 42 (18.8) 223
Retired 101 (82.1) 22 (17.9) 123
Keeping house 73 (70.2) 31 (29.8) 104
Unemployed unrel. 61 (81.3) 14 (18.7) 75
Student 33 (89.2) 4 (10.8) 37
Volunteer 23 (69.7) 10 (30.3) 33
Self-employed 15 (78.9) 4 ( 21.1) 19
Baseline Remission
Cross-sectional 455 (74.6) 155 (25.4) 610 0.010
Mean (SD)
Age [year] 39.4 (11.43) 40.1 (10.89) 39.6 (11.28) 0.293
PANSS Total 61.4 (16.20) 64.1 (16.66) 62.1 (16.37) 0.012
PANSS POS 2.1 (0.66) 2.3 (0.77) 2.1 (0.70) <0.001
PANSS NEG 2.4 (0.83) 2.4 (0.83) 2.4 (0.83) 0.969
PANSS DIS 2.1 (0.66) 2.2 (0.68) 2.1 (0.67) 0.274
PANSS HOS 1.5 (0.62) 1.7 (0.70) 1.6 (0.65) 0.003
PANSS DEP 1.9 (0.70) 2.0 (0.71) 1.9 (0.70) 0.015
QLS Total 1.8 (1.84) 1.4 (1.73) 1.7 (1.81) 0.001
QLS Interpersonal relations 2.8 (1.19) 2.7 (1.19) 2.8 (1.19) 0.074
QLS Instrumental role funct 2.5 (1.49) 2.2 (1.45) 2.4 (1.49) <0.001
CGI-S 3.0 (0.93) 3.3 (0.97) 3.1 (0.95) <0.001
No. of previous episodes 1.4 (1.53) 1.8 (2.74) 1.5 (1.91) 0.121
CGI-S: Clinical Global Impression – Severity, EPS: extrapyramidal symptoms, PANSS: Positive and Negative Symptoms Score, QLS: Heinrich Carpenter’s Quality of Life
Scale, SD: standard deviation.
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to baseline categories (PANSS and QLS scores at base-
line are reported in Table 4 and Figure 1).
By applying the rules based on Lipkovich et al. [4] and
described in the 'Outcomes measures' section to the
baseline scores of patients in this analysis, patients weregrouped into the 5 pre-specified categories. The largest
category (Category B: n = 434, 36.7%, see Table 4 and
Figure 1) consisted of patients with minimal symptoms
of schizophrenia according to the PANSS total score and
with seriously impaired functioning according to the
QLS score, followed by patients with moderate to severe
Table 3 Patient baseline characteristics by category at baseline
Categories n (%)
Characteristic (%) A N=162 B N=434 C N=208 D N=303 E N= 72 p-value
Study 0.068
HGLQ 32 (19.8) 123 (28.3) 38 (18.3) 68 (22.4) 0
HGKA 82 (50.6) 210 (48.4) 122 (58.7) 142 (46.9) 40 (55.6)
HGKB 48 (29.6) 101 (23.3) 48 (23.1) 93 (30.7) 32 (44.4)
Geographic Region 0.002
Western Europe 24 (14.8) 79 (18.2) 41 (19.7) 60 (19.8) 10 (13.9)
Eastern Europe 53 (32.7) 115 (26.5) 55 (26.4) 72 (23.8) 18 (25.0)
Americas 60 (37.0) 210 (48.4) 79 (38.0) 160 (52.8) 41 (56.9)
Other 25 (15.4) 30 (6.9) 33 (15.9) 11 (3.6) 3 (4.2)
Gender 0.491
Female 59 (36.4) 145 (33.4) 69 (33.2) 93 (30.7) 25 (34.7)
Male 103 (63.6) 289 (66.6) 139 (66.8) 210 (69.3) 47 (65.3)
EPS 0.013
Yes 12 (7.4) 58 (13.4) 30 (14.4) 48 (15.8) 16 (22.2)
Working Status1 <0.001
Paid work 72 (44.4) 50 (11.5) 70 (33.7) 28 (9.2) 3 (4.2)
Retired 19 (11.7) 61 (14.1) 15 (7.2) 23 (7.6) 4 (5.6)
Unemployed dis. 24 (14.8) 194 (44.7) 54 (26.0) 177 (58.4) 46 (63.9)
Cross-sectional remiss. <0.001
No 25 (15.4) 168 (38.7) 89 (42.8) 216 (71.3) 71 (98.6)
Yes 137 (84.6) 266 (61.3) 119 (57.2) 87 (28.7) 1 (1.4)
Mean (SD)
Age [year] 37.6 (10.6) 40.7 (11.6) 37.9 (11.1) 40.0 (11.2) 40.1 (11.3) 0.002
CGI-S 2.34 (0.85) 2.96 (0.89) 3.06 (0.84) 3.56 (0.76) 4.01 (0.84) <0.001
No. of previous episodes 1.07 (1.25) 1.60 (2.50) 1.34 (1.31) 1.54 (1.68) 1.85 (1.75) 0.017
1 Only the 3 largest categories (>10% of all patients) are shown as working status; 6 additional categories were defined and were included in the statistical
analysis (self employed, student, volunteer, keeping house, unemployed unrelated),CGI-S: Clinical Global Impression – Severity, EPS: Extrapyramidal Symptoms, SD:
standard deviation.
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function according to QLS (Category D: n = 303, 25.6%).
Category C (n = 208, 17.6%) comprised patients with
moderate PANSS total scores but good functioning
according to QLS, and Category A comprised patients
with minimal schizophrenic symptoms and good func-
tioning (n = 162, 13.7%). As only non-acutely ill patients
were eligible for participation in these studies, only 72
(6.1%) patients were grouped in Category E with severe
schizophrenic symptoms and impaired functioning.
Baseline category was significantly related to CGI-S,
presence of baseline EPS, working status, cross-sectional
remission, age, and number of previous episodes (Table 3).
Some differences regarding geographical regions were
found. In particular more patients from Eastern Europe
were categorized into Category A. However, this might re-
flect recruitment differences of patients by studies and is
considered as not clinically relevant.The rate of patients discontinued ranged from 26% to
42% by baseline category at 6 months and from 30% to
54% at 12 months (see Table 4). The lowest rates were
seen in Category A and the highest rates in the worst
categories (D and E).
Categorical changes after 6 months and 12 months of
treatment
The change of category membership from baseline to
the 6 months and 12 months assessments is shown in
Table 4 and Figure 1.
Overall at 6 months, 261 (26%) of all patients who
could improve in category (all but A) did improve, 471
(40%) of all patients remained in their baseline category,
and 55 (7%) of all patients who could get worse (all but
D and E) worsened. For 395 (33%) of all patients, a clas-
sification into category at 6 months was not possible be-
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Figure 1 Mean (95% CI) PANSS and QLS total score over time
by baseline category.
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provement was seen in >30% of patients in baseline Ca-
tegories C and D but for less than 15% in baseline
Category B. Worsening was seen in about 20% of
patients in baseline Category A and was <5% in baseline
Categories B and C.
The proportion of patients improving (239; 24%) or
worsening (48; 6%) after 12 months of OLAI treatment
was similar to those proportions seen at 6 months. The
proportion of patients who could not be classified due to
either discontinuation or missing data after 12 months
was 44% (523).
Table 5 shows the PANSS Total score and QLS Inter-
personal and QLS Instrumental domain scores at base-
line, 6 months, and 12 months overall and by baseline
category and the cross-sectional and sustained remission
status assessed at baseline, 6 months, and 12 months.
Cross-sectional remission status improved in 199
patients (17%) from no remission at baseline to remis-
sion at 6 months. Worsening from baseline remission to
no remission at 6 months occurred in 29 patients (2%).Remission status sustained at 6 months in 395 (33%) of
all patients. Sustained remission after 12 months was
achieved by 476 (40%) patients, only 49 (4%) of those
patients in cross-sectional remission at baseline did not
achieve sustained remission at 12 months.
Baseline predictors associated with improvement
The single variable logistic regression analyses found a
significant influence of a number of baseline covariates on
categorical improvement of patients at 6 and 12 months.
All variables with a significant influence on categorical im-
provement (except baseline category) are summarized in
Table 1.
Based on these, the stepwise multiple logistic regres-
sion analyses were performed for categorical improve-
ment at 6 months and 12 months. The significant
predictors identified from the stepwise multiple logistic
regression are shown in Table 1. An odds ratio estimate
greater than 1 indicates higher chances for improve-
ment. Odds ratios were calculated based on an increase
of 1 unit of the baseline value for continuous scales or
compared to a reference category at baseline for catego-
rical variables.
The odds for achieving a better category at 6 months
and 12 months were better for patients with a higher
(worse) baseline PANSS POS. In contrast, 6 month ca-
tegorical improvement was more probable for patients
with a lower (better) baseline CGI-S. All other variables
that were significant as single predictors lost their sig-
nificance in the joint model and were excluded by the
stepwise procedure. The shaded variables were not
entered in the model due to the fact that they were
derived from other variables as described in the statis-
tical procedure section.
Discussion
The majority of patients who stayed on 6 months main-
tenance treatment with OLAI improved or at least main-
tained their symptoms and functioning level as measured
by membership in 5 pre-specified categories. Improve-
ments from baseline occurred in all categories where this
was possible. Improvements in clinical symptoms were
also evident when assessing remission as an alternative ef-
ficacy parameter. The proportion of patients in cross-
sectional remission increased markedly from baseline to
6 months, and about 3/4 of the patients on OLAI treat-
ment achieved sustained remission according to Andreasen
criteria after 12 months [5].
Discontinuation rates in this pooled analysis are diffi-
cult to interpret since in some instances the reasons for
drop-out were linked to specific characteristics of the
studies, e.g. planned study termination after 6 months of
treatment in HGKA, randomization to fixed dosing
schedules in HGKA, or limitation to a maximum dose
Table 4 Patient categories at baseline, 6 months and 12 months, and change of categories at 6 months and 12 months











A 162 (14%) 86 26 7 0 0 43 (27%) N.A. 33 (20%)
B 434 (37%) 61 210 9 12 1 141 (33%) 61 (14%) 13 (3%)
C 208 (18%) 68 16 61 8 1 54 (26%) 68 (33%) 9 (4%)
D 303 (26%) 14 80 18 62 2 127 (42%) 112 (37%) N.A.
E 72 (6%) 3 14 3 18 7 27 (38%) 20 (28%) N.A.
Missing 3 (0.3%) 0 0 0 0 0 3
Total 1182 (100%) 232 (20%) 346 (29%) 98 (8%) 100 (8%) 11 (1%) 395 (33%) 261 (26%) 55 (7%)











A 162 (14%) 83 22 7 1 0 49 (30%) N.A. 30 (19%)
B 434 (37%) 58 169 7 11 4 185 (43%) 58 (13%) 15 (3%)
C 208 (18%) 62 21 36 3 0 86 (41%) 62 (30%) 3 (1%)
D 303 (26%) 20 60 16 43 1 163 (54%) 96 (32%) N.A.
E 72 (6%) 7 12 4 8 4 37 (51%) 23 (32%) N.A.
Missing 3 (0.3%) 0 0 0 0 0 3
Total 1182 (100%) 230 (19%) 284 (24%) 70 (6%) 66 (6%) 9 (1%) 523 (44%) 239 (24%) 48 (6%)
Patients improving from baseline to 6 months/1 year are indicated in bold. Patients worsening from baseline to 6 months/1 year are indicated in bold italics. 1%
to the column total across baseline categories; 2% to the row total within baseline category N.A.: not applicable.
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continuing before the 6 month analysis was moderate
(29%). The variables associated with early disconti-
nuation might suggest a certain bias due to patients with
worsening symptoms discontinuing more frequently.
However, only a minority of patients discontinued due
to lack of efficacy. Discontinuation rates were similar to
results from other studies in non-acute schizophrenic
patients using long-acting risperidone [14-16] and the
majority of patients in the poor baseline categories
remained in the study.
The dropout rates encountered in this analysis and the
heterogeneity of the analysis population due to the dif-
fering designs of the source studies are a limitation of
the current analysis, and might have led to a bias by
retaining only patients with an acceptable or positive re-
sponse to OLAI treatment during the course of the stu-
dies. Regarding study design important differences are
the different durations of pre-treatment at baseline and
the fact that HGKA was a double blind study whereas
HGLQ and HGKB were open-label studies. Also, no
consistent information about concomitant psychosocial
treatment was available and the impact of this could not
be included in the current analyses. In addition, due to
the study design of the source studies no comparison to
other antipsychotic treatments was possible and no across-
study procedures for maintaining interrater-reliability
were performed.The majority of the patients in our analysis was clinic-
ally stable and was classified in Categories A, B, and C.
Patients with residual psychotic symptoms were assigned
to the unfavorable Categories D and E. Our analysis,
looking at outcome at discrete points in time, is not
well-suited to evaluate the frequency of acute relapses.
However, very few patients worsened to Category E,
representing a status of severe psychosis. Generally, the
risk of symptom exacerbation in patients initially doing
well on OLAI treatment was small.
Logistic regression analyses identified a significant as-
sociation of PANSS positive symptoms at baseline with
categorical improvement after 6 months and 12 months,
indicating that patients with acute baseline positive
symptoms had better chances to improve over time.
CGI-S at baseline was also associated with categorical
improvement at 6 months, however with better odds for
improvement in patients with low CGI-S at baseline. We
suggest that PANSS positive symptoms reflect the
current psychotic symptoms of a patient and these may
vary strongly over time, depending on the course of dis-
ease and in particular treatment compliance, leading to
an improvement when effective antipsychotic treatment
is continuously provided by the depot formulation. In
contrast, CGI-S may measure the general status of the
patient as assessed by the physician, who may include
historical knowledge about the patient, the disease his-
tory, and the overall level of functioning of the patient.
Table 5 PANSS total score, QLS functional domain scores, and remission at baseline and changes at 6 Months and at
12 months
Categories
Scores A – (N)=162 B – (N)=434 C – (N)=208 D – (N)=303 E – (N)=72 Overall – (N) = 1182
PANSS Total
Baseline 45.56 (9.22) 55.29 (11.19) 64.91 (12.80) 71.50 (10.74) 93.63 (14.64) 61.53 (16.12)
6 months −4.39 (8.95) −6.41 (11.09) −10.80(12.98) −9.73 (12.56) −24.90(21.70) −8.77 (13.14)
12 months −3.79 (11.55) −6.32 (12.14) −12.94(12.78) −12.63(13.11) −30.39(20.72) −9.75 (14.29)
QLS Interpersonal
Baseline 3.75 (1.03) 2.48 (1.00) 3.56 (1.02) 2.22 (1.03) 2.00 (0.98) 2.77 (1.19)
6 months 0.02 (0.85) 0.38 (0.91) 0.11 (0.87) 0.41 (0.80) 0.42 (0.85) 0.28 (0.88)
12 months 0.20 (0.89) 0.47 (0.99) 0.03 (0.92) 0.46 (0.82) 0.61 (0.83) 0.34 (0.93)
QLS Instrumental
Baseline 4.26 (0.73) 1.75 (0.97) 4.11 (0.64) 1.50 (0.94) 1.27 (0.99) 2.53 (1.49)
6 months −0.34 (1.13) 0.52 (1.16) −0.10 (0.97) 0.51 (1.13) 0.43 (1.07) 0.26 (1.16)
12 months −0.19 (1.04) 0.70 (1.27) −0.10 (1.02) 0.68 (1.25) 1.05 (1.19) −0.41 (1.25)
Remission – based on observed cases
n (%) A B C D E Overall
Baseline - cross-sectional 137 (84.6) 266 (61.3) 119 (57.2) 87 (28.7) 1 (1.4) 610 (51.6)
6 months - cross-sectional 114 (95.8) 235 (80.2) 125 (81.2) 104 (59.1) 15 (33.3) 594 (75.5)
6 months - sustained 99 (83.2) 159 (54.3) 90 (58.4) 46 (26.1) 1 (2.2) 395 (50.2)
12 months - cross-sectional 106 (93.8) 204 (81.9) 101 (82.8) 95 (67.9) 15 (42.9) 521 (79.1)
12 months - sustained 104 (92.0) 191 (76.7) 95 (77.9) 76 (54.3) 10 (28.6) 476 (72.2)
PANSS: Positive and Negative Symptoms Score, QLS: Heinrich Carpenter’s Quality of Life Scale, SD: standard deviation.
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tor for treatment outcomes. Surprisingly, some other fac-
tors previously reported as predictors for maintenance
treatment outcomes in schizophrenic patients in previous
studies could not be corroborated in the present analysis.
There were no significant differences found for gender, re-
mission status at baseline, disease history, and age [17-19].
However, there were some differences in the type of
patients and follow up duration. For example, Möller et al.
[17] observed only patients first hospitalized and over a
much longer duration of up to 15 years. Furthermore in a
more recent review of Emsley et al. [20] only early treat-
ment response, baseline symptom severity and subjective
well-being were mentioned as important known predictive
factors for remission in schizophrenia.
Outcomes of schizophrenia treatments can be assessed
by many measures in several dimensions. As no single in-
dividual measure seems to be sufficient for covering a
complex disorder as schizophrenia, there have been efforts
to find more comprehensive approaches to measure the
effectiveness of treatment and patient outcomes [21,22].
The categories used in the present analysis originate from
a statistical approach based on well-established sympto-
matic (PANSS) and functional (QLS) measures combining
2 main dimensions of schizophrenia. Since these catego-
ries were derived from a cluster analysis, they do not referto arbitrary definitions but provide evidence-based criteria
for categorization. This approach provides a more com-
prehensive measure for treatment outcomes in schizo-
phrenia which deserves further evaluation.
In the present sample, even patients in the best category
had not achieved good levels of functioning at baseline.
This result reflects the serious impact of schizophrenia on
functioning in comparison with other psychotic or non-
psychotic disorders. When very strict criteria including
functioning are used for definition of recovery, only a
small proportion of patients with schizophrenia will be
able to achieve this target [23-25].
Conclusions
Overall, this pooled analysis shows that patients who re-
main on maintenance treatment with OLAI can improve
both their schizophrenic symptoms and their function-
ing. We have shown that there is a potential to treat and
improve patients who are already stable. High levels of
acute psychotic symptoms usually discourage clinicians
and patient relatives and may lead to a suboptimal use
of treatment options in severely ill patients. However,
our results show that improvement is possible despite
severe symptoms and that intensive treatment (e.g.
OLAI with regular follow-up) can lead to a significant
improvement for patients. Finally, this analysis provides
Peuskens et al. BMC Psychiatry 2012, 12:130 Page 11 of 11
http://www.biomedcentral.com/1471-244X/12/130evidence that a composite assessment of schizophrenic
patients including symptom severity and functioning can
be used for the description of the patient population.
This approach could also be used for the assessment of
treatment options in clinical practice.
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